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SUMMARY
Introduction: Pentavalent antimonials are the first drug of choice in the treatment of tegumentary leishmaniasis. Data on ototoxicity 
related with such drugs is scarcely available in literature, leading us to develop a study on cochleovestibular functions. Case Report: 
A case of a tegumentary leishmaniasis patient, a 78-year-old man who presented a substantial increase in auditory threshold with 
tinnitus and severe rotatory dizziness during the treatment with meglumine antimoniate, is reported. These symptoms worsened in 
two weeks after treatment was interrupted. Conclusion: Dizziness and tinnitus had already been related to meglumine antimoniate. 
However, this is the first well documented case of cochlear-vestibular toxicity related to meglumine antimoniate. 
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INTRODUCTION
Pentavalent antimonials are still the first drug of choice in the 
treatment of tegumentary leishmaniasis (TL), although they can cause 
adverse reactions such as electrocardiographic, liver, pancreas and 
kidney function alterations4. Myalgia, arthralgia and fever are common 
and vestibular alterations such as dizziness are occasionally observed2,12. 
However, we could not find any well documented report on cochlear and 
vestibular toxicity caused by meglumine antimoniate.
The present case report of ototoxicity of meglumine antimoniate 
(MA) was diagnosed during an ongoing longitudinal study in patients 
with TL treated at IPEC-FIOCRUZ, Rio de Janeiro, Brazil. All patients 
were submitted to vestibular evaluation (Vectoelectronystagmography - 
VENG) and audiologic evaluation (conventional pure tone audiometry, 
distortion product otoacoustic emissions - DPOAE and tympanogram) 
before, during (every ten days) and up to three months after treatment 
discontinuation or normalization of alterations. During the monitoring 
process, patients were submitted to physical examination, blood 
biochemistry, complete blood count and ECG. The normal values of 
the laboratory tests were: glucose (70-110 mg/dL); urea (15-38 mg/
dL); creatinine (0.6-1.3 mg/dL); amylase (25-115 mg/dL); lypase 
(114-286 mg/dL); (aspartate transaminase (AST) (15-37 U/L); alanine 
transaminase (ALT) (12-78 U/L); alkaline phosphatase (ALP) (50-136 
U/L); gamma glutamyl transpeptidase (GGT) 15-85 U/L.
Ototoxicity was considered the onset of dizziness and/or hearing loss 
(with a unilateral or bilateral audiometric threshold increase equal to or 
greater than 20 dB, at one or more frequencies, or a 10dB increase at two 
adjacent frequencies) during treatment with meglumine antimoniate1,6.
This study was submitted to and approved by the Research on Human 
Beings Ethics Committee of the Evandro Chagas Research Institute of 
the Oswaldo Cruz Foundation (IPEC- FIOCRUZ), under the number 
0055.0.009.000-07. The patient agreed to participate in the study and 
signed a free informed consent form.
CASE REPORT
A seventy-eight year-old man, without previous skin lesions or skin 
scars consistent with tegumentary leishmaniasis (TL), evolved during 
the last year with volume increase in the nasal pyramid to the right side, 
nasal obstruction, epistaxis to manipulation of nasal cavities, crusting 
and occasional cacosmia. He also had 117 mg/dL glucose; 48 mg/dL 
urea; 1.5 mg/dL creatinine; 78 mg/dL amylase; 22 U/L AST; 30 U/L 
ALT; 74 U/L ALP. Systemic arterial hypertension was treated with 25 
mg/day hydrochlorothiazide 20 mg/day nifedipine, 2 mg/day doxazosin 
mesylate, besides 50 mg SOS sodium diclofenac, due to chronic muscle 
pain. He reported bilateral hearing loss for the last seven years, but he 
denied tinnitus, dizziness, noise exposure or family history of auditory 
and/or vestibular symptoms. Otoscopy was normal and the endoscopic 
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examination of the upper aero-digestive tract presented infiltration of the 
right nasal wing and the entire mucosa of the right nasal cavity, preventing 
progression of optics. There was also infiltration of the vestibular 
region, anterior nasal septum and head of the left inferior turbinate, with 
discrete crusts, as well as absence of mucosal lesions in the pharynx 
and larynx. Syphilis and fungal serologies were negative. TL serologies 
performed were: 1:40 indirect immunofluorescence technique and 
ELISA reactor. A nasal biopsy was performed. Fragment cultures were 
negative to Leishmania, mycobacteria and fungus. The histopathological 
examination revealed chronic granulomatous inflammation with 
necrosis. The immunohistochemistry with anti-Leishmania serum 
showed occasional amastigote forms and polymerase chain reaction 
was positive to Leishmania. A pre-treatment audiometric study showed 
mild to severe sensorineural hearing loss, tritone mean at 500-1000-
2000 Hz of 53dB and 62dB, in the right and left ears, respectively. 
Additionally, he presented bilateral type A tympanogram and bilaterally 
absent distortion product otoacoustic emissions (DPOAE). Treatment 
with meglumine antimoniate (MA) (Glucantime® from Sanofi Aventis) 
was initiated at a maximum daily dose of three ampoules (weight 72 kg; 
dose 16.9 mgSb+5/kg/day) for 30 days.
On the twelfth day of treatment, the patient returned with herpes 
zoster in the buttock (dermatome S1) and myalgia, and acyclovir cream, 
urea cream and 50 mg of sodium diclofenac if pain were prescribed. 
He was asymptomatic from the cochlea-vestibular point of view, but 
presented a 10 dB increase of the auditory threshold at 6 kHz and a 15 dB 
increase at 8 kHz in the left ear (LE). On the twenty-sixth day, treatment 
was discontinued due to cutaneous rash, scaling of lower limbs, difficulty 
in walking, arthralgia, myalgia, hand tremor, dry oral mucosa, anorexia 
and loss of weight (-3 kg). He also presented frequent severe rotatory 
dizziness lasting some minutes with no associated vagal symptoms, 
without worsening of hearing complaints previously reported. VENG 
was normal and the audiometry showed a 20 dB increase at 6 KHz and 
a 25 dB increase at 8 KHz in the LE. He also had 153 mg/dL glucose; 83 
mg/dL urea; 322 mg/dL amylase; 181 U/L AST; 174 U/L ALT; 112 U/L 
ALP; 175 U/L GGT) and QTc 0.46. Sixteen days after the treatment was 
discontinued, he maintained rare non-rotatory dizziness lasting seconds, 
without objective worsening of hearing complaints, but with tinnitus, and 
he had fallen two days before. Pure tone audiometry presented severe 
worsening of LE auditory thresholds (10 dB increase at 250 Hz; 10 dB 
increase at 500 Hz; 15 dB increase at 1 KHz; 25 dB increase at 2 KHz; 
30 dB increase at 3 KHz; 15 dB increase at 6 KHz; and 45 dB increase at 
8 KHz) and VENG was within the normal range, although with reduction 
of more than 50% of the previous value of Angular Velocity of the Slow 
Component of Nystagmus in degrees per second (AVSC º/s) at 18 ºC. He 
had 118 mg/dL glucose; 30 mg/dL urea; 90 mg/dL amylase; 41 U/L AST; 
71 U/L ALT; 155 U/L ALP; 128 U/L GGT) and QTc 0.33. Twenty-eight 
days after treatment interruption, he no longer had tinnitus and dizziness 
remained of mild intensity and lasting seconds. He walked adequately 
and myalgia and tremors had improved. Pure audiometry showed no 
more increments consistent with ototoxicity criterion. He had 110 mg/dL 
glucose; 1.4 mg/dL creatinine; 105 mg/dL amylase; 371 mg/dL lypase; 
34 U/L AST; 43 U/L ALT; 115 U/L ALP; 80 U/L GGT) and QTc 0.33. 
As the patient still presented mucosa lesions 90 days after treatment 
interruption, he was successfully treated with 150 mg/day (2.2 mg/kg/
day) liposomal amphotericin B, up to an accumulated dose of 1800 mg, 
when it was discontinued due to serum creatinine value of 1.6 mg/dL, 
without worsening of hearing and/or dizziness complaints. A year and 
four months later, he did not present worsening of hearing complaints 
when compared to the beginning of treatment with MA, neither tinnitus 
nor dizziness, and the audiometry was not consistent with ototoxicity 
criterion and VENG was within the normal range, with AVSC in the LE 
at 18 ºC returning to values similar to the beginning of symptomatology. 
The DPOAE examination remained absent during the entire monitoring. 
Graphs 1 (Pure tone audiometry through air conduction of the left ear of 
a patient during the monitoring process, IPEC, FioCruz, Rio de Janeiro, 
2011) and 2 (Variations of Angular Velocity of the Slow Component of 
Nystagmus in degrees per second (AVSC º/s) of the patient during the 
monitoring process - IPEC, FioCruz, Rio de Janeiro, 2011) show the 
variations in pure tone audiometry and of the angular velocity of the slow 
component of nystagmus, during the patient’s follow-up.
DISCUSSION
We reported the first well documented case on cochlear-vestibular 
toxicity related to MA diagnosed during a longitudinal study with patients 
with TL submitted to vestibular and auditory evaluation when under 
treatment with antimonials.
The patient had been using other drugs for a long term, without 
dizziness or tinnitus complaints, before beginning treatment with MA, 
thus we assumed that those drugs did not influence the development 
of such symptoms. This hypothesis is favored by the time factor, since 
the worsening of auditory thresholds, tinnitus and dizziness started 
Graph 1 - Pure tone audiometry through air conduction of the left ear of a patient during monitoring - IPEC, FioCruz, Rio de Janeiro, 2011.
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after initiating MA treatment, following a reasonable time after drug 
administration, when the levels of this drug were well established in body 
fluids and tissues7, and it was confirmed because signs and symptoms 
improved when the treatment was discontinued, thus showing that a 
relationship between these adverse effects and MA is likely to be true. 
Although infection has not responded to treatment with MA, we do not 
believe that the outcome of the infection may have had an influence on the 
MA ototoxicity, since the disease itself would not be capable of causing 
the sensorineural changes found in this patient. The success of treatment 
with pentavalent antimonials depends on the peak value reached in serum 
or the maintenance of a minimum inhibitory concentration in serum, 
during most part of the time3. The finding that pentavalent antimonial is 
rapidly excreted in the urine, resulting in sub therapeutic serum levels 
in a few hours, led to the conclusion that the risk of cumulative toxicity 
is low and that intermittent therapeutic schemes are pharmacologically 
inconsistent3,7. However, in vivo evidences of meglumine antimoniate 
conversion from Sb5+ into Sb3+ and the accumulation of Sb3+ in the tissues 
suggest that Sb3+ production could be responsible for the sustained activity 
of the drug, both therapeutic and toxic. Just a small conversion of the 
Sb5+ drug seems to occur during the phase of rapid excretion, however, 
it is followed by a phase of slow excretion of a high proportion of Sb3+ 
with a half-life of more than 50 days7. This pharmacokinetic behavior 
could explain the worsening of the auditory thresholds and AVSC at 18 ºC 
alterations up to 28 days after discontinuing the treatment. Additionally, 
the patient had mucosal leishmaniasis which requires a treatment of 30 
days with MA. Therefore, ototoxicity could not have been so intense, if 
he had cutaneous leishmaniasis which requires a shorter treatment time 
up to 21 days. 
However, the use of other ototoxic drugs may lead to more frequent 
cochlear-vestibular toxicity which, in this particular case, could have been 
enhanced by the use of doxazosin mesylate and hydrochlorothiazide, both 
potentially ototoxic13. Non-steroidal anti-inflammatory drugs (NSAIDs) 
are related to reversible ototoxicity, with 1% to 3% incidence17. They can 
induce vestibular disorders, less frequent than auditory disorders, such 
as tinnitus and hearing loss. The effect is more metabolic than structural, 
usually reversible, and proportional to the plasma concentration of the 
toxic drug. However, the patient had been using this drug for the last 
seventeen years, sporadically, without reporting any audio vestibular 
symptom5,14,17.
Our study failed in not performing high frequency audiometry, since 
cochleotoxicity can occur, initially or solely, at the high frequency series 
from 9 to 20 kHz. Thus, the use of audiometry at conventional frequencies 
only, could have hindered an earlier and/or bilateral alteration in this 
case study1. The role of effective monitoring of the cochlear function 
in early detection of ototoxicity of DPOAE has been reported, through 
drop of their responses18. In this patient, this assessment was hampered 
because the DPOAE were already absent at the beginning of treatment. 
However, the evolution of the reported case was documented through 
serial examinations16. 
The occurrence of subclinical ototoxicity of some drugs1 diagnosed 
by audiometry control has been described. To our knowledge, this is the 
first controlled case study of ototoxicity related to MA. This explains 
the fact that we could not find in literature references of hearing loss 
caused by this drug. 
The most frequently reported adverse effects of pentavalent antimonials 
were musculoskeletal pain, gastrointestinal disturbances, mild to moderate 
headache, electrocardiographic QTc interval prolongation, mild to moderate 
increase in liver and pancreatic enzymes and significant suppression of 
mean lymphocyte and platelet counts11,19. However, cochlear-vestibular 
toxicity is not frequently reported. Tinnitus and dizziness had already 
been reported during ML treatment with tartar emetic9. Considering a 
recent report stating that Sb3+ levels represent more than 30% of total Sb 
concentrations in Glucantime®, we can suppose that Glucantime® may 
not be so different from trivalent antimonial tartar emetic and that Sb3+ 
may account for its ototoxicity15. The patient studied in the present case 
was a senior, male, and presented renal, hepatic and pancreatic toxicity. 
Dizziness associated to the use of meglumine antimoniate has already been 
reported regarding females, aged 60 years or more and related to pancreatic 
toxicity2. Because of its toxicity, meglumine antimoniate should be used 
with caution in patients older than 60 years8. 
As for vestibular toxicity, the most common finding is hyporeflex or 
Graph 2 - Variations of Angular Velocity of the Slow Component of Nystagmus in degrees per second (AVSC °/s) of the patient during monitoring - IPEC, FioCruz, Rio de Janeiro, 2011. 
RE - Right Ear; LE - Left Ear.
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simply normal reflex associated to vestibular complaints of the patient. 
Besides, it has been described that a reduction of 50% or more of the 
vestibular system, in at least one ear, indicates vestibular toxicity10. 
Although all the examinations of this case presented AVSC at 18 ºC within 
normal reflex values, it is evident that a reduction of more than 50% of 
this value occurred from the beginning of symptoms to 16 days after 
treatment, and that, a year later, the patient being asymptomatic, there was 
a return to values similar to the beginning of symptoms. Unfortunately, 
we do not have values before treatment to compare. Apparently tinnitus 
and dizziness are not related, since time of maximum tinnitus alteration 
did not correspond to that of maximum dizziness. 
At the end of the ongoing longitudinal study, we intend to clarify 
some aspects related to the ototoxicity of meglumine antimoniate, such 
as dose dependence, relation with treatment duration, reversibility or not, 
as well as the associated risk factors. 
RESUMO
Primeiro relato de ototoxicidade pelo antimoniato de meglumina
Introdução: Antimoniais pentavalentes são os fármacos de 
primeira escolha no tratamento da leishmaniose tegumentar. Dados de 
ototoxicidade relacionados a tais fármacos são escassos na literatura, o 
que nos levou a desenvolver um estudo de funções cócleo-vestibulares. 
Relato de caso: Relatamos caso de paciente masculino de 78 anos 
com leishmaniose tegumentar, que apresentou aumento significativo 
dos limiares auditivos com zumbido e tontura rotatória grave durante o 
tratamento com antimoniato de meglumina. Os sintomas pioraram até 
duas semanas após a interrupção do tratamento. Conclusão: Tontura 
e zumbido já tinham sido associados ao antimoniato de meglumina. 
Entretanto, este é o primeiro caso bem documentado de toxicidade 
cócleo-vestibular relacionado ao antimoniato de meglumina.
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